A comprehensive analysis of a retrospective cohort on a substantial scale, encompassing 392,246 cases of HER2‐0 BC and 743,770 cases of HER2‐low BC sourced from the National Cancer Database, found minimal prognostic differences between HER2‐low and HER2‐0 breast cancer.25 This evidence concerns the gene ERBB2 and breast cancer.